Russia Develops Revolutionary mRNA Cancer Vaccine ‘EnteroMix’
Early trials show 100% safety and effectiveness, offering hope against rising cancer cases in India and worldwide
- India recorded 1.6 million new cancer cases and 900,000 deaths in 2024.
- Russia develops mRNA-based cancer vaccine EnteroMix.
- Phase 1 trial shows 100% safety and effectiveness.
- Vaccine is personalized based on each patient’s tumor genetics.
- Early results show tumor shrinkage or slowed growth.
GG News Bureau
Moscow, 8th Sep: Cancer cases are rising sharply across the globe, with India recording nearly 1.6 million new cases and 900,000 deaths in 2024, according to WHO data. Experts estimate that one in every nine to ten Indians faces a lifetime risk of cancer. Amid this alarming trend, a breakthrough has emerged from Russia, where scientists claim to have developed a pioneering cancer vaccine named EnteroMix.
The vaccine, based on mRNA technology, has successfully completed its Phase 1 clinical trials, proving both safe and 100% effective in early tests. Patients involved in the trial reportedly experienced no major side effects, and results showed tumor shrinkage or slower growth.
Medical experts describe this as a potential game-changer in oncology, comparing its impact to that of COVID-19 mRNA vaccines, which trained the immune system to fight the virus. Similarly, EnteroMix instructs the body’s cells to produce specific proteins that help the immune system identify and attack cancer cells.
Dr. Mohit Sharma, Clinical Director and Head of Medical Oncology at Marengo Asia Hospital, Faridabad, explained that EnteroMix is personalized for each patient, designed according to the genetic profile of the tumor. This allows the vaccine to specifically target and destroy cancer cells unique to each individual.
Unlike chemotherapy or radiation, the vaccine reportedly has minimal side effects and could significantly improve patients’ quality of life. Researchers say it can be developed rapidly thanks to the mRNA platform.
Currently, the vaccine is being tested for colorectal cancer, glioblastoma (brain cancer), and ocular melanoma (eye cancer). If it succeeds in Phase 2 and Phase 3 trials involving larger patient groups, it could revolutionize cancer treatment worldwide.
For India, where cancer incidence is climbing rapidly, EnteroMix offers a ray of hope, potentially transforming cancer from a life-threatening disease into a manageable condition.
